Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Camp4 Therapeutics Corp(CAMP US)

$4.33-0.367.68%Ext:$4.58+0.255.71%(Pre-Market · 12:00:18 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Camp4 Therapeutics Corp(CAMP US)

$4.33-0.367.68%Ext:$4.58+0.255.71%(Pre-Market · 12:00:18 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees
CAMP US​
Ask AI

Camp4 Therapeutics Corp — Company Profile

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Joshua Mandel-Brehm
Headquarters
Cambridge, MA, US
IPO Date
Oct 11, 2024
Employees
48
Website
www.camp4tx.com

Key Metrics

Price
$4.00
Market Cap
$251.01M
Revenue (TTM)
$1.29M
Net Income (TTM)
$-18331000.00
EPS (TTM)
-0.32
P/E (TTM)
-2.91
P/B (TTM)
8.12
Dividend Yield
0.00%
ROE (TTM)
-59.32%
ROA (TTM)
-17.38%
Operating Margin
-10.10%
Beta
1.36

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

Website
www.camp4tx.com
Location
Cambridge, MA, US
Phone617-651-8867
Employees48
CEOJoshua Mandel-Brehm
Sector
Health Care
Industry
Pharmaceuticals
IPO DateOct 11, 2024

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data04:12AM
  • CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears9 Nov
  • CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates5 Nov
  • CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights5 Nov
  • CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release29 Oct
  • CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union27 Oct
  • CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease20 Oct
  • CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference14 Oct
  • CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages30 Sep
  • CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-00229 Sep
  • Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript28 Sep
  • CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-00228 Sep
  • CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder10 Sep
  • CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 20268 Sep
  • CAMP4 to Participate in Upcoming Investor Conferences1 Sep
  • Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec31 Aug
  • Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec18 Aug
  • CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates13 Aug
  • CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights13 Aug

Key Stats

Trading

Px/Chg 1D$4.00 / +4.17%
Prev Close$4.41
% of 52Wk H56.77%
Avg Volume204.93K
Beta1.36
Mkt Cap251.01M
FD Mkt Cap93.46M

Float

Shrs Out/Float62.75M / 43.33M
Short Float0.47%
Days to Cover2.34
Stock Repurchased$0.00

Current Valuation

EV153.93M
EV/EBITDA-2.95
EV/Sales39.13
P/B8.12
P/S63.81
FCF Yield-4.37%
ROE-59.32%
ROA-17.38%
Current Ratio6.15

Estimates

P/E-2.91
Est P/E0.00
Est EPS-0.21
Est PEG0.00

Valuation

Metric5Yr AvgMay '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-6.48-0.79-5.23-13.41
Price / Sales286.1262.82605.53190.01
Price / Book Value4.340.654.427.96
Price / Free Cash Flow3.40-0.8933.49-22.39
ENTERPRISE VALUE METRICS
Enterprise Value79.2-14.4103.2148.8
Enterprise Value / Sales129.78-22.13296.50114.98
Enterprise Value / EBITDA-6.630.28-8.32-11.85
Enterprise Value / EBIT-6.400.27-8.08-11.38

Financials

Full Financials
Millions USD5Yr CAGR (%)Feb '22Feb '23Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-67%295.8-0.40.73.5
Gross Income-64.9%121.9-0.40.71.9
EBITDA—7.5-44.1-50.2-51.4-50.4
EBIT35.8%-15.3-45.0-51.9-53.1-52.1
Net Income26.8%-31.1-44.2-49.3-51.8-80.4
EPS (Diluted)31.7%-0.88-0.90-4.07-2.66-2.65
BALANCE SHEET
Cash & ST Inv4.7%91.183.238.464.0109.5
Total Assets-26.4%402.3102.554.978.3117.8
Total Liabilities-31.7%322.1180.1178.715.270.1
Total Shareholder Equity-12.2%80.2-77.5-123.763.147.7
CASH FLOW
Net Operating Cash Flow62.7%-4.2-38.5-44.2-45.6-29.6
Cap Ex-61.9%-13.3-4.0-0.7-0.4-0.3
Free Cash Flow14.2%-17.5-42.6-44.8-46.0-29.8

Enterprise Value Bridge

Millions USD10 Nov '26
Price (As of 10 Nov '26)4.49
Basic Shares62.75
Market Cap281.8
Diluted Shares78.95
Fully Diluted Shares Outstanding78.95
Fully Diluted Market Cap354.5
+Consolidated Debt6.5
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-124.5
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value163.7

Segment data

Revenue

by Products and services

  • Product64%
  • Application Subscriptions And Other Services36%

Revenue

by Geography

  • United States63%
  • Emea19%
  • Latin America11%
  • Asia Pacific6%
  • All Other1%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

CAMP US​
Ask AI

Camp4 Therapeutics Corp — Company Profile

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Joshua Mandel-Brehm
Headquarters
Cambridge, MA, US
IPO Date
Oct 11, 2024
Employees
48
Website
www.camp4tx.com

Key Metrics

Price
$4.00
Market Cap
$251.01M
Revenue (TTM)
$1.29M
Net Income (TTM)
$-18331000.00
EPS (TTM)
-0.32
P/E (TTM)
-2.91
P/B (TTM)
8.12
Dividend Yield
0.00%
ROE (TTM)
-59.32%
ROA (TTM)
-17.38%
Operating Margin
-10.10%
Beta
1.36

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

Website
www.camp4tx.com
Location
Cambridge, MA, US
Phone617-651-8867
Employees48
CEOJoshua Mandel-Brehm
Sector
Health Care
Industry
Pharmaceuticals
IPO DateOct 11, 2024

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data04:12AM
  • CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears9 Nov
  • CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates5 Nov
  • CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights5 Nov
  • CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release29 Oct
  • CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union27 Oct
  • CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease20 Oct
  • CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference14 Oct
  • CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages30 Sep
  • CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-00229 Sep
  • Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript28 Sep
  • CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-00228 Sep
  • CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder10 Sep
  • CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 20268 Sep
  • CAMP4 to Participate in Upcoming Investor Conferences1 Sep
  • Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec31 Aug
  • Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec18 Aug
  • CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates13 Aug
  • CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights13 Aug

Key Stats

Trading

Px/Chg 1D$4.00 / +4.17%
Prev Close$4.41
% of 52Wk H56.77%
Avg Volume204.93K
Beta1.36
Mkt Cap251.01M
FD Mkt Cap93.46M

Float

Shrs Out/Float62.75M / 43.33M
Short Float0.47%
Days to Cover2.34
Stock Repurchased$0.00

Current Valuation

EV153.93M
EV/EBITDA-2.95
EV/Sales39.13
P/B8.12
P/S63.81
FCF Yield-4.37%
ROE-59.32%
ROA-17.38%
Current Ratio6.15

Estimates

P/E-2.91
Est P/E0.00
Est EPS-0.21
Est PEG0.00

Valuation

Metric5Yr AvgMay '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-6.48-0.79-5.23-13.41
Price / Sales286.1262.82605.53190.01
Price / Book Value4.340.654.427.96
Price / Free Cash Flow3.40-0.8933.49-22.39
ENTERPRISE VALUE METRICS
Enterprise Value79.2-14.4103.2148.8
Enterprise Value / Sales129.78-22.13296.50114.98
Enterprise Value / EBITDA-6.630.28-8.32-11.85
Enterprise Value / EBIT-6.400.27-8.08-11.38

Financials

Full Financials
Millions USD5Yr CAGR (%)Feb '22Feb '23Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-67%295.8-0.40.73.5
Gross Income-64.9%121.9-0.40.71.9
EBITDA—7.5-44.1-50.2-51.4-50.4
EBIT35.8%-15.3-45.0-51.9-53.1-52.1
Net Income26.8%-31.1-44.2-49.3-51.8-80.4
EPS (Diluted)31.7%-0.88-0.90-4.07-2.66-2.65
BALANCE SHEET
Cash & ST Inv4.7%91.183.238.464.0109.5
Total Assets-26.4%402.3102.554.978.3117.8
Total Liabilities-31.7%322.1180.1178.715.270.1
Total Shareholder Equity-12.2%80.2-77.5-123.763.147.7
CASH FLOW
Net Operating Cash Flow62.7%-4.2-38.5-44.2-45.6-29.6
Cap Ex-61.9%-13.3-4.0-0.7-0.4-0.3
Free Cash Flow14.2%-17.5-42.6-44.8-46.0-29.8

Enterprise Value Bridge

Millions USD10 Nov '26
Price (As of 10 Nov '26)4.49
Basic Shares62.75
Market Cap281.8
Diluted Shares78.95
Fully Diluted Shares Outstanding78.95
Fully Diluted Market Cap354.5
+Consolidated Debt6.5
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-124.5
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value163.7

Segment data

Revenue

by Products and services

  • Product64%
  • Application Subscriptions And Other Services36%

Revenue

by Geography

  • United States63%
  • Emea19%
  • Latin America11%
  • Asia Pacific6%
  • All Other1%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US